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Aims/hypothesis: We used Laser Doppler Fluximetry (LDF) to define "normal" endothelial function in a large
cohort of healthy children and adolescents and to evaluate skin microcirculation in paediatric patients with type 1
diabetes mellitus.
Methods: LDF was performed in 102 healthy children (12.8 ± 3.3 years of age; 48 male) and 68 patients (12.9 ± 3.3
years of age; 33 male). Duration of disease was 5.0 ± 3.97 years. Each participant sequentially underwent three
stimulation protocols (localized thermal hyperaemia with localized warming to maximum 40°C, iontophoretic delivery
of pilocarpine hydrochloride (PCH) and sodium nitroprusside (SNP)). The maximum relative increase in skin blood flow
and the total relative response, i.e. the area under the curve (AUC) to each stimulus (AUCheat, AUCPCH, AUCSNP) was
determined. In addition, the area of a right-angled triangle summarizing the time to and the amplitude of the first
peak, which represents the axon reflex mediated neurogenic vasodilation (ARR) was calculated.
Results: In healthy controls, AUCheat, AUCPCH, AUCSNP, and ARR turned out to be independent of sex, age, and
anthropometric values. Per parameter the 10th percentile generated from data of healthy controls was used as the
lower threshold to define normal endothelial function. Diabetic patients showed significantly reduced vasodilatative
response to either physical or pharmacological stimulation with SNP, whereas the response to PCH was comparable in
both cohorts. In patients compared to controls i) a significantly higher frequency of impaired vasodilatation in response
to heat and SNP was noted and ii) vascular response was classified as pathological in more than one of the parameters
with significantly higher frequency.
Conclusions/interpretation: Skin microvascular endothelial dysfunction is already present in about 25% of paediatric
type 1 diabetic patients suffering from type 1 diabetes for at least one year. Future studies are needed to assess the
predictive value of endothelial dysfunction in the development of long-term (cardio)vascular comorbidity in these
patients.
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Children suffering from type 1 diabetes mellitus are prone
to increased cardiovascular morbidity and mortality on
the long term [1-4]. Microvascular endothelial function is
thought to be affected early, relative to the onset of type 1
diabetes, and an impaired endothelial function marks the
beginning of the decline to clinically relevant cardiovascu-
lar disease [5,6]. An increased carotid intima-media* Correspondence: dagmar-christiane.fischer@med.uni-rostock.de
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distribution, and reproduction in any mediumthickness (cIMT) as a marker of macrovascular disease is
seen early during the development of cardiovascular dis-
ease [7]. In contrast to cIMT, which can be measured dir-
ectly and with reasonable effort, the assessment of
endothelial function in-vivo is not an easy task. Several
methods, e.g. laser Doppler fluximetry (LDF), laser Dop-
pler imaging (LDI), flow mediated dilation (FMD), and
videocapillaroscopy are available [8,9]. With these me-
thods the blood flow throughout the microcirculatory net-
work is monitored and endothelial function is assessed
indirectly from the effects of exogenous manipulation of
blood flow. Moreover, the anatomical localization of theMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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vasodilatation have to be considered [8,9]. Thus, adequate
controls are required for almost every study, making the
investigation of endothelial function especially in paediat-
ric patients even more challenging. Nevertheless, several
studies comparing children suffering from type 1 diabetes
and age-matched healthy controls have consistently dem-
onstrated that vascular function and cIMT are already im-
paired in diabetic children [2-4,6,10-15]. Apart from
methodological differences for the assessment of endothe-
lial function and despite the inherent consistency of the
results reported in each of these studies the definition of
"normal" endothelial function remains poor and the indi-
vidual patient barely benefits from this investigations. We
used LDF together with localized thermal hyperaemia as
well as iontophoretic delivery of pilocarpine hydrochloride
(PCH) as a stable alternative for acetylcholine chloride
and sodium nitroprusside (SNP) to i) assess and define
"normal" vasodilatory function in a large cohort of healthy
children and adolescents, ii) compare the data from paedi-
atric patients with type 1 diabetes to those from healthy
controls in order to determine existence and frequency of
cases below normal cut-off, and, iii) classify endothelial
(dys)function in children and adolescents with type 1 dia-
betes and to compare the incidence between groups and
factors relating to it.Research design and methods
Study design
The study received appropriate ethics committee ap-
proval from the institutional review board in accordance
with the Declaration of Helsinki. Subjects and/or their
parents gave written and informed consent for partici-
pating in the study.
A total of 102 healthy children and young adults (48
males and 54 females) with a mean age of 12.8 years
(range: 6–18 years) were investigated. Participants were
recruited from schools in Rostock. Paediatric patients
with type 1 diabetes and a minimum age of 6 years, suf-
fering from type 1 diabetes mellitus for at least one year
and treated at our institution were invited to participate.
A total of 68 patients (33 males) consented and was en-
rolled within a 12-month period. Inclusion criteria: age 6–
18 years, C-peptide below 0.3 nmol/l, stable therapeutic
regimen with either multiple daily insulin injections (MDII)
or continuous subcutaneous insulin infusions (CSII, pump
therapy) for at least 3 months. Both, healthy controls and
patients were excluded in any case of febrile illness during
the last three months, chronic inflammatory-/rheumatic
disease, (e.g. Crohn’s disease, rheumatoid arthritis), hepa-
titis, HIV, glucocorticoid treatment, liver-, renal-, or cardiac
failure, hereditary dyslipidaemia, skin conditions prohibiting
LDF, pregnancy or tumoral diseases. All patients were freeof retinal lesions and neuropathy; microalbuminuria was
noted in one patient only.
Methods
All participants were seen in our outpatient clinic in the
afternoon. Demographic and clinical data were gathered
by interview and chart review (i.e. mode of therapy, mean
daily insulin dosages, mean HbA1c during the last year),
respectively. All investigations were conducted at room
temperature (climatized room at 22°C) and in a quiet en-
vironment, i.e. in the absence of powerful audio-visual and
other mental stimuli, and all subjects were tested individu-
ally. Participants were asked not to consume nicotine, caf-
feine and alcohol for at least 12 h before measurements
and to take a light meal or snack at latest 2 h before the
scheduled examination time. Patients do adhere to their
individual therapeutic scheme. A trained physician mea-
sured weight and height throughout the study using elec-
tronic scales and a fixed stadiometer. Blood pressure (BP)
was measured according to the updated Task Force Report
on high blood pressure by using an oscillometric device
(Dinamap 1846SX; Critikon, Tampa, USA). Calculations of
individual age- and sex-related standard deviation scores
(SD scores) for height, weight, BMI and BP were done as
previously described [16-18]. Patients were classified as
hypertensive in case of BP values above the height- and
sex-related 95th percentile. Carotid intima-media-thick-
ness (cIMT) was assessed by highresolution B-mode ultra-
sound using a EUB-525 Duplex Scanner (Hitachi, Tokyo/
Japan) equipped with a 10-MHz linear array transducer
and echo-tracking system [19]. The mean of four mea-
surements performed in each of the two carotid arteries
was used for the calculation of height-related SDS values
[20,21].
Laboratory and clinical data
In patients, the actual HbA1c expressed as percentage of
total haemoglobin as well as serum lipids (total choles-
terol, triglycerides, LDL-cholesterol and HDL-cholesterol)
and blood glucose levels were determined in the institute
laboratory. The mean HbA1c during the last 12 months
and the mean insulin dosage per day were calculated.
Assessment of skin microcirculation
Two laser probes, allowing simultaneous recording of skin
microcirculation at different sites and conditions, a dual
channel Laser Doppler Monitor (VMS-LDF2), a circular
heating device with a central hole for positioning of one of
the probes (SH02), a circular perspex iontophoresis cham-
ber together with a counter electrode and the iontopho-
retic device (Moor Iontophoresis Controller) were used.
All instruments were computer-controlled with corre-
sponding software (MoorVMS-PC V2.0), which in turn
recorded data from the laser Doppler probes with a
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monthly and the perspex chambers were carefully
rinsed with tap water and distilled water after each use.
Pilocarpine hydrochloride (Caesar & Loretz GmbH,
Hilden, Germany) was prepared at a final concentra-
tion of 1% (w/w) in 0.5% methylcellulose (pharmaceut-
ical grade; Sigma-Aldrich, Taufkirchen, Germany)
aliquoted and stored at 4°C until use. We used PCH as
a pharmaceutically approved substitute for acetylcho-
line, which was barely available at the time this study
was conducted. Sodium nitroprusside (SNP, analytical
grade, Merck KG, Darmstadt, Germany) was freshly
prepared at a final concentration of 0.1% (w/w) in 0.5%
methylcellulose. In order to minimize unspecific ef-
fects, both solutions were brought to an ionic strength
of 154 mmol/l by addition of sodium chloride [22].
Protocol
Skin microcirculation was investigated essentially as de-
scribed [23]. Participants acclimatized for at least 15
min and rested supine throughout the recording, which
was performed in an acclimatized room (22°C). During
the acclimatization period the skin at the volar surface
of the forearm was gently cleaned with a skin cleanser
(Octenisept, Schülke, Norderstedt, Germany). The probes
used to record data at sites of baseline and stimulated
blood flow were attached approximately 5 cm apart using
double-sided adhesive tape (Berger Medizintechnik Gm-
BH, Gleisdorf, Austria) avoiding hair, broken or pigmented
skin, and visible blood vessels. Each participant underwent
three stimulation protocols, i.e. localized heating for induc-
tion of thermal hyperaemia, iontophoretic delivery of pilo-
carpine hydrochloride (PCH) and sodium nitroprusside
(SNP) and this sequence of events was kept constant
throughout the study. The probes were repositioned after
each run to avoid additive effects and/or localized exhaus-
tion of vasodilatatory capacity.
Thermal hyperaemia
Flow was recorded with the heating device set to 31°C for
five minutes.Thereafter, the temperature was gradually in-
creased to 40°C (increments of 2°C and finally 3°C every 2
minutes) and kept at 40°C for a further 30 minutes to en-
sure maximum vasodilatation [24]. In parallel, unstimu-
lated blood flow was recorded at the control site, i.e.
approximately 5 cm apart from the site of stimulation.
Pharmacological stimulation
Endothelial-dependent and -independent vascular re-
sponses were measured using low-current iontophoresis
of PCH and SNP, respectively. The iontophoresis cham-
ber holding the laser probe in a central compartment
and containing the drug solution, the counter electrode
and the control laser probe were fixed 4 to 5 cm apartto the volar surface of the forearm. The iontophoresis
chamber and the counter electrode were connected to the
iontophoresis controller and flux was continuously
recorded on both sites. In order to obtain a cumulative
dose–response curve, current was applied with increasing
duration and intensity (100 μA for 10 s, 1mC; 200 μA for
10 s, 2 mC; 200 μA for 20 s, 4 mC; 200 μA for 40 s, 8 mC;
and 200 μA for 80 s, 16 mC) [23]. Dosages were separated
by 60 s, 60 s, 90 s, and 120 s and after delivery of the last
dosage the flux was recorded for an additional 180 sec-
onds. The cumulative dosages of PCH (78.6 μg; anodal
current) and SNP (95.9 μg; cathodal current) are similar at
a molar base (0.3 mmol each).
Data analysis
The mean flux measured at both sites over a period of
five minutes before stimulation (baseline flux) was used
for normalization of data subsequently recorded at the
respective site [25-27]. In particular, the automatically
recorded table containing data on time and skin blood
flow (SkBF) at both sites relative to the underlying
stimulation protocol were used. For either site the mean
of SkBF over 5 minutes (baseline flux) was calculated
and used for normalization of flux data measured at ei-
ther site during stimulation. The normalized amplitude
of the axon reflex response together with the normalized
flux at the control site (first maximum occurring shortly
after the heating device was set to 40°C) as well as the
mean normalized amplitude throughout the last five mi-
nutes of localized warming (maxSkBFheat) were derived
from these tables. For calculation of AUCheat, we inte-
grated the normalized SkBF signals over the time of local-
ized heating (i.e. 40 min) at both sites and the difference
between both values is given. The two sides of the right-
angled triangle, reflecting time-to and intensity of the axon
reflex are the normalized amplitude and the time it took
from the moment the heating device was set to 40°C (i.e. 9
min after start of the heating device) to peak (Figure 1). In
the case of iontophoresis, the mean of the normalized flux
signals recorded at either site for an additional period of
3min after delivery of the last drug dosage were used as
maxSkBFPCH and maxSkBFSNP, respectively. For calcula-
tion of AUCPCH and AUCSNP we integrated the normal-
ized flux signals over the total time of iontophoresis, i.e.
490s of stimulation plus 180s for maximum vasodilation.
Statistical analysis
SigmaPlot 10.0 (Systat Software GmbH, Erkrath, Germany)
and SPSS 15.0 (SPSS Inc., Chicago, USA) were used for
graphical presentation and statistical analysis, respectively.
Normal distribution was evaluated by the Kolmogorov-
Smirnow test and comparison between groups was done
using Student’s t-Test or Mann–Whitney-U test, if appro-
priate. Nonrandom associations between categorical
Figure 1 Parameters calculated from the normalized time
related response to local heat. A, normalized axon reflex response,
t, time to the axon reflex response starting from the time that the
local skin temperature was set to 40°C (arrow head, 9min. after start
of local warming). The area under the curve (AUCheat) equals the
maximum response to localized heating, with beginning and end of
the time interval set to 0 and 40 min, respectively. Insert: the
amplitude of the axon reflex (A) together with the time required to
peak (t) are summarized as the area of a triangle. The time interval
begins 9 min after start of localized warming, i.e. the time the
heating device was set to 40°C.
Table 1 Characteristics of patients and controls
Patient Controls p
n 68 (33 m/35f) 102 (48 m/54f)
Age [year] 12.93 ± 3.34 12.84 ± 3.30 0.963
13.4 (6.3-19) 13.2 (6.4-19)
Height
Absolute [cm] 157 ± 18.8 158 ± 18.4 0.720
159 (111–195) 162 (116–191)
SDS 0.04 (−2.65-2.7) 0.37 (−2.03-2.10) 0.076
Weight
Absolute [kg] 50.9 ± 16.3 48.0 ± 17.0 0.190
52.6 (21.0-95.0) 48.5 (18.0-92.0)
SDS 0.49 (−2.91-13.7) 0.17 (−0.15-3.84) 0.080
BMI
Absolute [kg/m2] 19.7 (14.0-39.3) 18.2 (12.5-28.1) 0.008
SDS 0.23 (−2.74-3.92) −0.23 (−3.20-2.51) 0.002
Systolic blood pressure
Absolute [mm Hg] 117.1 ± 13.0 110.0 ± 11.1 <0.001
117 (80–147) 110 (89–165)
SDS 0.91 (−2035-2.94) 0.05 (−2.44-1.58) <0.001
Diastolic blood pressure
Absolute [mm Hg] 71.1 ± 9.4 65.6 ± 10.1 <0.001
72 (39–94) 65.0 (40–105)
SDS 0.65 (−1.65-2.35) −0.26 (−3.23-2.0) <0.001
























Actual HbA1c [%] 8.65 ± 1.8 5.37 ± 0.22 <0.001
8.3 (6.0-14.5) 5.4 (4.9-6.0)
Mean Hba1c [%] 8.62 ± 1.2
8.4 (6.6-11.7)
Values are given as mean ± SD or median and range.
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values are two-sided and a p-value below 0.05 was consid-
ered significant. Data is given as mean ± SD or median and
range, where appropriate.
Results
Patients and healthy controls were fairly comparable
with respect to age, height and weight, whereas BMI and
blood pressure was significantly higher in patients com-
pared to controls (Table 1). Interestingly, mean cIMT
values did not differ significantly between patients and
controls. Patients received multiple daily insulin injec-
tions (MDI; n=45) or continuous subcutaneous insulin
infusions (CSII; n=23) by means of an insulin pump. All
participants completed the examinations as intended
and all of the procedures were well tolerated. Per partici-
pant, we had a set of four parameters, reflecting the nor-
malized local vasodilatative capacity in response to
physical (heat; AAR and AUCheat) and pharmacological
stimulation (AUCPCH, AUCSNP). In healthy controls, these
parameters were independent of sex and age as well as of
absolute and standardized height, weight or BMI (Figure 2
and data not shown). Similarly, in healthy controls and pa-
tients, pubertal stage did not affect the responses to either
heat, PCH or SNP. By contrast, patients' absolute and
standardized weight and BMI each showed a positive cor-
relation with ARR (ARR vs. weight: r= 0.31; ARR vs.
weight-SDS: r=0.37; ARR vs. BMI: r=0.39; and ARR vs.
BMI-SDS: r=0.34; each p<0.005) (Figure 3). Categorizationof the patient cohort according to a normal or patho-
logical response in either one of the parameters describing
vasodilatative capacity and subsequent comparison of
Figure 2 ARR, AUCheat, AUCPCH and AUCSNP as a function of age in healthy children. ARR (A), AUCheat (B), AUCPCH (C) and AUCSNP (D) as a
function of age in healthy children (open symbols: male; closed symbols: female).
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vealed no significant differences. Furthermore, in both co-
horts a strong correlation between AUCheat and ARR as
well as a weaker one between AUCheat and AUCSNP was
noted, while the response to PCH was apparently inde-
pendent from the responses to either heat or SNP (Figure 4
and data not shown).
In general, children with type 1 diabetes mellitus showed
significantly reduced vasodilatative response to either
physical (heat; p<0.01) or pharmacological stimulation
with SNP (p<0.001) respectively, whereas the response to
PCH was comparable in both cohorts (Figure 5). Given,
that a low rather than high cutaneous response to induced
vasodilatation reflects impairment of microvascular func-
tion, per parameter the 10th percentile was used as the
lower normal cut-off, i.e. values above this threshold are
considered to reflect normal vasodilatative capacity, while
those below are deemed pathological. This approach con-
firmed that an impaired vasodilatative response with re-
spect to stimulation with heat and SNP was significantly
more frequent among children with diabetes (Table 2 andFigure 3 Correlation between AAR and weight-SDS (A) and betweenFigure 4). Interestingly, the vascular response was classi-
fied as pathological in more than one of the parameters
described above with significantly higher frequency in pa-
tients compared to controls (17 out of 68 patients (25%)
vs. 10 out of 102 controls (10.8%); p<0.05). In line with
this, in patients with a pathological ARR also significantly
lower AUCheat, AUCPCH and AUCSNP was observed (each
p< 0.05). By contrast, neither cIMT-SDS nor blood pres-
sure, duration of disease, mode of insulin therapy or
serum lipids differ significantly when patients were catego-
rized according to pathological results in either one of the
four parameters defined (data not shown). However, endo-
thelial independent vasodilatation was better preserved in
patients with an insulin pump compared to those on MDI
therapy (AUCSNP = 64.2; 12.9 - 215 and 37.9; 1–149; CSII
vs. MDI; p<0.01).
Discussion
Type 1 diabetes is an established risk factor of cardiovas-
cular disease, which starts from endothelial dysfunction
and quietly develops over many years. The risk ofARR and BMI-SDS (B) in patients. A: r= 0.37; B: r=0.34, each p<0.005.
Figure 4 Correlation between AUCheat and AAR (A, C) and between AUCheat and AUCSNP (B, D) in healthy children (A, B) and patients
(C, D). A: r= 0.92, p<0.001; B: r=0.37, p<0.001; C: r=0.80, p<0.001; D: r=0.32, p<0.05; per parameter the 10th percentile is indicated by a horizontal
or vertical line, respectively.
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which several can be modulated, e. g. obesity, nutritional
behavior, physical activity, mode of insulin therapy, com-
pliance with and adherence to therapeutic recommenda-
tions. The onset of type 1 diabetes is most frequently in
childhood and in view of the need for a life-long therapy,
compliance to therapy is a serious issue, especially during
puberty. Sensitizing paediatric patients and parents to the
inherent risks of severe comorbidities which become clin-
ically visible and relevant only years after diagnosis of type
1 diabetes is challenging. Therefore, the detection of evenFigure 5 Comparison of AUCheat, AUCPCH and AUCSNP in
healthy controls (open bars) and diabetic patients (grey bars).subtle and at this stage potentially reversible nerve damage
and aberrations from a normal endothelial function are of
great relevance. On the one hand, this is a very logical ap-
proach to demonstrate diabetes-related complications at
an early stage, on the other hand "normal" is hard to
define.
Although LDF has been used to investigate microcir-
culation and/or the axon reflex mediated neurogenic
vasodilation for more than 20 years, these issues have
rarely been investigated in healthy children. Instead,
LDF was used to evaluate endothelial function relative
to characteristics of the disease or to compare cohorts
rather than to counsel an individual patient. With LDF
relative changes in skin blood flow occurring in a small
volume (~1mm3) of tissue in response to an exogenous
stimulus are accurately detected and quantified [8,26].
Due to the high sampling rate of the probes one is left
with huge amounts of data reflecting the time, course
and amount of vasodilatation secondary to physical or
pharmacological stimulation. Instead of using several pa-
rameters describing amplitude and slope of the vascular
response as a function of dose, we decided to present
the individually normalized total response, i.e. for thermal
hyperaemia a triangle reflecting the intensity of the axon
reflex (AAR) and the areas under the curve reflecting the
total effects of localized heating (AUCheat) or
Table 2 Local thermal hyperaemia, SNP- and PCH-induced vasodilation in healthy controls and patients with type
1 diabetes
Controls Patients p
ARR (cut-off: 4.3 [raPU*min])
Median (range) 9.05 (0.40-64.9) 7.22 (0.62-27.6) 0.003
Below cut-off 10/102 18/68 (26.5%)
AUCheat(cut-off:153 [raPU*min])
Median (range) 399 (45–1053) 301 (0–988) 0.006
Below cut-off 10/102 16/68 (23.5%)
maxSkBFheat(cut-off:5.9 [raPU])
Median (range) 15.4 (1–40) 10.8 (1–36) 0.007
bBelow cut-off 10/102 12/68 (17.6%)
AUCSNP (cut-off:18.6 [raPU*min])
Median (range) 64.6 (0–244) 41.7 (0–215) <0.001
Below cut-off 10/102 17/68 (25%)
maxSkBFSNF (cut-off:3.0 [raPU])
Median (range) 12.1 (1–47.8) 7.4 (1–30.9) <0.001
Below cut-off 10/102 14/68 (20.6%)
AUCPCH (cut-off:6.6 [raPU*min])
Median (range) 30.6 (0.158) 27.9 (0–175) 0.427
Below cut-off 10/102 8/68 (11.8%)
maxSkBFPCH (cut-off:2.1 [raPU])
Median (range) 8.0 (1–45.6) 7.0 (1–35.4) 0.100
Below cut-off 10/102 10/68 (14.7&)
Per parameter, median and range as well as the number of individuals with an inadequately low response to exogenous stimulation of skin microcirculation
are given.
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AUCPCH), respectively. Thus, we obtained data reflecting
nerve and vascular function.
In healthy subjects none of these parameters was asso-
ciated with sex, age or height. Moreover, in patients and
healthy subjects pubertal stage did not affect the re-
sponse to either stimulus. However, the broad and
skewed distribution of the results led us to the definition
of the 10th percentile as the lower threshold and dis-
criminator between normal and impaired endothelial
function in response to a given stimulus. Although this
approach enables the classification of individual results
and to compare subgroups of patients, i.e. those with an
insufficient and those with sufficient vasodilatation none
of the clinical characteristics, i.e. duration of disease, gly-
caemic control, serum lipids, blood pressure or cIMT,
differed significantly between patients with preserved
and impaired endothelial function. This might be due, at
least in part, to the overall rather low vascular comor-
bidity in this patient cohort. In addition, more subtle
measures of glycaemic control, e.g. continuous glucose
monitoring, may have uncovered a significant association
between glycaemic control and endothelial function in ourpatient cohort. None of the patients showed signs of dia-
betic retinopathy and only one and five out of 68 patients,
respectively, presented with microalbuminuria and an in-
creased cIMT. However, in patients with an ARR below
the 10th percentile endothelial dependent and independ-
ent vasodilatation was also impaired. Thus, even we were
unable to associate these findings with any of the charac-
teristics of the underlying disease, the combination of an
impaired response to either stimulus strongly indicates
endothelial dysfunction. By contrast, healthy individuals
usually showed such a low response for only one of the
three stimuli. Although LDF might be replaced in future
by more sensitive and robust laser Doppler imaging tech-
niques, and introduction of LDF into routine clinical care
is rather unlikely for several reasons, data on "normal"
endothelial function in healthy children is a prerequisite
for counseling of patients participating in experimental re-
search. Previously conducted studies consistently demon-
strated an impaired endothelial function in paediatric
patients suffering from type 1 diabetes [2,4,10]. However,
studies differ with respect to the number of patients and
controls as well as to the exogenous stimulus (iontopho-
retic delivery of acetylcholine [10]; localized heat,
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duction of postocclusion reactive hyperaemia [4]. Regard-
less of this and even of the different presentation of results,
our study confirmed the expected impairment of thermal
hyperaemia and NO-mediated (endothelial independent)
vasodilatation in diabetic children compared to their
healthy peers [2]. By contrast, in our study the response to
PCH was rather low and even similar in patients and con-
trols. First of all, this reflects the overall lower vasodilatory
capacity of acetylcholine (and by analogy also PCH) com-
pared to SNP and localized warming [29-31]. Furthermore,
assessing differences between rather small absolute results
of an experimental investigation, i.e. the response to PCH,
requires both, highly accurate measurements with low in-
dividual variability and the examination of large numbers
of individuals. Thus, the rather high variability of PCH
iontophoresis and the limited number of patients may have
obscured the difference between groups. Apart from this,
our study and that from Khan et al. [2] are comparable
with respect to i) the number, sex and age of patients in-
vestigated, ii) the duration of disease, iii) glycemic control,
and, iv) daily insulin dosages, whereas the site of measure-
ment (dorsum of the foot vs. volar surface of the forearm)
and the mode of therapy (MDI and CSII vs. MDI) were dif-
ferent. Although categorization of our patients according
to therapy revealed no statistically significant differences
between patients on MDI and CSII therapy respectively,
the frequency of pathological responses to heat and SNP
were higher in patients on MDI therapy compared to con-
trols, while no such difference between patients on CSII
therapy and healthy controls was detectable. Whether or
not this points to CSII as a more physiological mode of in-
sulin therapy compared to MDI remains to be seen. If this
holds true, one would expect lower glycaemic variability as
the main contributor to endothelial and neuronal damage.
Our study has some methodological limitations regarding
assessment of skin blood flow. The individual variability of
LDF is rather high and LDI might have been better suited
for this type of study. The investigation of children re-
quired adaptation of previously established protocols, i.e.
the maximum temperature for localized warming was set
to 40°C instead of 42°C and blood pressure was measured
only once before starting the LDF measurements. Al-
though the stage of the menstrual cycle may have af-
fected individual results, one could reasonably expect a
similar and random distribution of this variable among
both groups.
Regardless of these limitations, we could clearly dem-
onstrate that skin microcirculation is already impaired in
about 25% of paediatric patients suffering from type 1
diabetes for at least one year. Future studies are needed
to assess the predictive value of endothelial dysfunction
for the development of long-term (cardio-)vascular co-
morbidity in these patients.Abbreviations
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